S-8 EX-FILING FEES 0001553643 Fees to be Paid Fees to be Paid N/A 0001553643 1 2026-06-17 2026-06-17 0001553643 2 2026-06-17 2026-06-17 0001553643 2026-06-17 2026-06-17 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-8

Relmada Therapeutics, Inc.

Table 1: Newly Registered Securities

                                       
Security Type   Security Class Title   Notes   Fee Calculation
Rule
  Amount Registered   Proposed Maximum Offering
Price Per Unit
  Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                       
Equity   Common stock, $0.001 par value per share:   (1)   Other   2,000,000   $ 6.4280   $ 12,856,000.00   0.0001381   $ 1,775.41
Equity   Common stock, $0.001 par value per share:   (2)   Other   8,328,908   $ 6.4280   $ 53,538,220.62   0.0001381   $ 7,393.63
                                       
Total Offering Amounts:   $ 66,394,220.62         9,169.04
Total Fee Offsets:               0.00
Net Fee Due:             $ 9,169.04

 

__________________________________________
Offering Note(s)

(1) Represents additional shares of common stock, $0.001 par value per share (“Common Stock”), of Relmada Therapeutics, Inc. (the “Company”) reserved for issuance under the Company’s 2021 Equity Incentive Plan (as amended, the “2021 Plan”). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an additional indeterminate amount of shares to be offered or sold pursuant to the 2021 Plan and shares that may become issuable under the 2021 Plan by reason of certain corporate transactions or events, including any share dividend, share split, recapitalization or any other similar adjustment of the outstanding Common Stock.

Represents the number of shares and shares issuable pursuant to stock option awards outstanding under the 2021 Plan.

Estimated pursuant to Rule 457(h) solely for purposes of calculating the aggregate offering price and the amount of the registration fee based upon a weighted average of the exercise prices of outstanding options previously granted.
(2) Represents additional shares of common stock, $0.001 par value per share (“Common Stock”), of Relmada Therapeutics, Inc. (the “Company”) reserved for issuance under the Company’s 2021 Equity Incentive Plan (as amended, the “2021 Plan”). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an additional indeterminate amount of shares to be offered or sold pursuant to the 2021 Plan and shares that may become issuable under the 2021 Plan by reason of certain corporate transactions or events, including any share dividend, share split, recapitalization or any other similar adjustment of the outstanding Common Stock.

Represents the number of shares and shares issuable pursuant to stock option awards available for future awards under the 2021 Plan.

Estimated solely for the purpose of calculating the registration fee computed pursuant to Rule 457(c) and (h), upon the average of the high and low prices of the Company’s common stock of $6.428, quoted on the Nasdaq stock Market on 16, 2026.